Literature DB >> 6154441

Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: a controlled study.

F S Haddad, W S Risk.   

Abstract

Isoprinosine (inosiplex), a proposed antiviral agent, was given to 18 patients with subacute sclerosing panencephalitis (SSPE). No great improvement occurred in any patient soon after treatment, but 2 patients did improve substantially several months after discontinuing Isoprinosine. Spontaneous improvement also occurred in 4 out of 96 controls. Because of the variable natural history of SSPE, differences in clinical improvement between treated patients and controls were not significant. Changes in serial measles antibody titers did not correlate with therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6154441     DOI: 10.1002/ana.410070216

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

2.  Immunoglobulin G subclass antibodies to measles virus in patients with subacute sclerosing panencephalitis or multiple sclerosis.

Authors:  P D Mehta; B A Patrick; W Sobczyk; J Kulczycki; J Woyciechowska-Camenga; D Camenga; H Thormar
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Cerebrospinal fluid IgG changes in subacute sclerosing panencephalitis in the various stages of the disease and during isoprinosine therapy.

Authors:  M Poloni; B Rocchelli; G Lanzi; F Rosano Burgio; D Besana
Journal:  Ital J Neurol Sci       Date:  1981-05

Review 4.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

5.  Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

Authors:  B Anlar
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

6.  Subacute sclerosing panencephalitis in a brother and sister. Therapeutic trial of fibroblast interferon.

Authors:  C R Bartram; J Henke; J Treuner; M Basler; A Esch; W Mortier
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

7.  Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases.

Authors:  T Nakamura; N Miyasaka; R M Pope; N Talal; I J Russell
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

Review 8.  Subacute sclerosing panencephalitis.

Authors:  Ravindra Kumar Garg
Journal:  J Neurol       Date:  2008-10-14       Impact factor: 4.849

Review 9.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

10.  Clinical conundrum: status epilepticus culminating into acute dystonia myoclonus.

Authors:  Madhuri Laxman Khilari; Praveen Kumar Sharma
Journal:  BMJ Case Rep       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.